ALB and pulmonary edema: However, the clinical trial ALIAS (Albumin in Acute Ischemic) showed that treatment with intravenous albumin in stroke patients was not associated with improved outcome at 90 days, and was associated with increased rates of HT and pulmonary edema [73].